Bromfenac: all 45 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract SurgeryRecruitingNCT07178639Not applicable
• Bromfenac Sodium Hydrate Eye Drops in Familial Exudative VitreoretinopathyRecruitingNCT05107921Phase 2
• Effects of Bromfenac on Macular Thickness After Phacoemulsification SurgeryCompletedNCT06785090Phase 4Results posted
• Control of Pain in Intravitreal Injections Using Topical NSAIDsCompletedNCT04343222Phase 4Results posted
• Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery SubjectsCompletedNCT01808547Phase 3Results posted
• Comparison Study of ISV-303 to DuraSite Vehicle in Cataract Surgery SubjectsCompletedNCT01576952Phase 3Results posted
• Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.CompletedNCT01535443Phase 1Results posted
• Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract SurgeryCompletedNCT01387464Phase 2Results posted
• Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract SurgeryCompletedNCT01367249Phase 3Results posted
• Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%CompletedNCT01310127Phase 4Results posted
• Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery VolunteersCompletedNCT01190878Phase 1/2Results posted
• A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)CompletedNCT01023724Phase 4Results posted
• A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing PhacoemulsificationCompletedNCT01021761Phase 4Results posted
• A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing PhacoemulsificationCompletedNCT01001806Phase 4Results posted
• Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract SurgeryCompletedNCT00853970Phase 3Results posted
• Safety and Efficacy of an Ophthalmic Solution in Dry Eye DiseaseCompletedNCT00758784Phase 2Results posted
• Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract SurgeryCompletedNCT00704418Phase 3Results posted
• Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract SurgeryCompletedNCT00703781Phase 3Results posted
• Efficacy and Safety of Bromfenac Ophthalmic SolutionCompletedNCT00585975Phase 2Results posted
• Efficacy of Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Cystoid Macular Edema Following Cataract PhacoemulsificationCompletedNCT07696104Phase 4
• Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour PeriodCompletedNCT07090044Phase 4
• Effectiveness of Periocular Drug Injection in CATaract SurgeryTerminatedNCT05158699Phase 3
• PCME Prevention in Patients With NPDRCompletedNCT04940338Phase 4
• Effect of Bromfenac on Pain Related to Pterygium SurgeryCompletedNCT04022811Phase 4
• Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical TrialCompletedNCT03886779Phase 4
• NSAID vs Steroid in Trabeculectomy Wound ManagementStatus unknownNCT03751059Phase 4
• PGE2 Levels in Patient Treated With NSAIDsCompletedNCT03597867Phase 3
• Bromfenac Versus Dexamethasone After Cataract SurgeryCompletedNCT03317847Phase 4
• Topical 0.1% Bromfenac Sodium and Prostaglandin E2 Inhibition in Cataract SurgeryCompletedNCT02681679Not applicable
• NSAIDs and PGE2 Levels in Vitrectomy PatientsCompletedNCT02361645Phase 3
• Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract SurgeryCompletedNCT02137161Phase 4
• PRevention of Macular EDema After Cataract SurgeryCompletedNCT01774474Phase 3
• Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)CompletedNCT00828477Phase 4
• Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.CompletedNCT00758628Phase 4
• Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract SurgeryCompletedNCT00758199Phase 4
• Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical CareCompletedNCT00698724Phase 4
• Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%CompletedNCT00595543Phase 4
• Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction PhaseCompletedNCT00520260Phase 4
• Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to LaserStatus unknownNCT00491166Phase 1
• Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal ThickeningCompletedNCT00469781Phase 4
• Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug EffectsCompletedNCT00469690Phase 4
• Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema.WithdrawnNCT00438243Phase 2
• Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic ConjunctivitisCompletedNCT00423007Phase 3
• Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract SurgeryCompletedNCT00333918Phase 3
• Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract SurgeryCompletedNCT00198445Phase 3

← Bromfenac overview